Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1975-1984

  Chen, R A ^a   Tu, Y ^a   Cao, Y ^a   Liu, L ^a   Liang, YingMin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Dexamethasone; Doxorubicin and Dexamethasone (VAD); Multiple Myeloma; Thalidomide; Vincristine

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; M PROTEIN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HERPES ZOSTER; HUMAN; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 80155161859     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900544     Document Type: Article

References (47)

1. Greenlee RT, Murray T, Bolden S: Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Kyle RA, Therneau TM, Rajkumar SV, et al: Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 2004; 101: 2667-2674.
3. Drach J, Kaufmann H, Urbauer E, et al: The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126: 441-447.
4. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
5. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-89.
6. Harousseau JL, Mathiot C, Attal M, et al: Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed patients: updated results of the IFM 2005/01 trial. Blood 2007; 110(suppl): 139 [abstract 450].
7. Rajkumar SV: Multiple myeloma: the death of VAD as initial therapy. Blood 2005; 106: 2-3.
8. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with highdose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
9. Cavo M, Benni M, Ronconi S, et al: Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica 2002; 87: 934-942.
10. Alexanian R, Haut A, Khan AU, et al: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
11. Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991; 9: 444-448.
12. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
13. Kyle RA, Rajkumar SV: Multiple myeloma. Blood 2008; 111: 2962-2972.
14. Hulin C, Virion J, Leleu X, et al: Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. J Clin Oncol 2007; 25(suppl): 8001.
15. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-4629.
16. Mani A, Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776-4789.
17. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
18. Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426: 895-899.
19. Hideshima T, Mitsiades C, Akiyama M, et al: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-1534.
20. Vacca A, Ribatti D, Roncali L, et al: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
21. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
22. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
23. Rajkumar SV, Kyle RA: Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005; 80: 1371-1382.
24. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
25. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
26. Chamberlain MC, Johnston SK, Glantz MJ: Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 2009; 66: 74-78.
27. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, 31 March 2003 (available at: http://ctep.cancer.gov).
28. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
29. Cavenagh JD, Oakervee H, UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces: Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18-26.
30. Dimopoulos MA, Anagnostopoulos A, Weber D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21: 4444-4454.
31. Cavo M, Zamagni E, Tosi P, et al: First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
32. Palumbo A, Bertola A, Falco P, et al: Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318-324.
33. Zervas K, Dimopoulos MA, Hatzicharissi E, et al: Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15: 134-138.
34. Rajkumar SV, Richardson PG, Hideshima T, et al: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639.
35. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
36. Hideshima T, Chauhan D, Hayashi T, et al: Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspasedependent downregulation of gp130 in multiple myeloma. Oncogene 2003; 22: 8386-8393.
37. Stewart AK, Fonseca R: Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23: 6339-6344.
38. Richardson PG, Barlogie B, Berenson J, et al: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977-2981.
39. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
40. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
41. Berenson JR, Yang HH, Sadler K, et al: A phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944.
42. Berenson JR, Yellin O, Patel R, et al: A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2009; 15: 1069-1075.
43. Neben K, Moehler T, Benner A, et al: Dosedependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377-3382.
44. Nguyen TT, Adair LS, He K, et al: Optimal cutoff values for overweight: using body mass index to predict incidence of hypertension in 18-to 65-year-old Chinese adults. J Nutr 2008; 138: 1377-1382.
45. Argyriou AA, Zolota V, Kyriakopoulou O, et al: Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON 2010; 15: 435-446.
46. Manochakian R, Miller KC, Chanan-Khan AA: Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist 2007; 12: 978-990.
47. Zangari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-1615.